LordsMed, the healthcare division of LordsMark Industries, has taken a significant leap in preventive healthcare by launching a set of 10 world-class bio-chemistry reagents. In a press statement on Tuesday, the company said, filed under India patents, these re-agents boast an unprecedented 99.7 per cent accuracy, the highest sensitivity level, a generous shelf-life of 24 months, unique packaging, and competitive pricing. The re-agents aim to enhance the preventive healthcare mechanism for critical diseases, the statement read.
Manufactured at LordsMed's facility in Maharashtra, the re-agents are poised to make a substantial impact in the diagnostic industry. The company plans to distribute these re-agents to pathological labs, hospitals, and research institutes through its extensive Pan-India network of over 300 dealers.
Sachidanand Upadhyay, MD and CEO of LordsMark Industries stated, "The launch of our innovative re-agents addresses the growing demand for affordable and high-quality diagnostic solutions in India. With an emphasis on accuracy, sensitivity, and extended shelf life, our re-agents aim to redefine the framework for pre-emptive diagnostic interventions, especially for critical diseases. By securing Indian patents, we aim to gain global recognition and acceptance in international markets. With our robust manufacturing capacity and a vast distribution network, we are well-positioned to meet the escalating demand for quality re-agents globally."
LordsMed's manufacturing facility in Vasai is complemented by upcoming facilities in Lucknow, Uttar Pradesh, and Silvassa, Union Territory of Dadra and Nagar Haveli, which are set to establish new benchmarks in Asia for production capacity and quality standards. LordsMark Industries has strategically collaborated with esteemed institutions like IIT Bombay, Bhabha Atomic Research Centre (BARC), and others to develop world-class patent products, signalling a transformative era in the diagnostic industry.